Task Force IV: Cardiovascular Effects of Emerging Infectious Diseases and Biological Terrorism Threats Basic, Clinical, and Population Science Research and Training Needs by Madjid, Mohammad et al.
Task Force IV: Cardiovascular Effects of Emerging
Infectious Diseases and Biological Terrorism Threats
Basic, Clinical, and Population Science Research and Training Needs
Mohammad Madjid, MD, Russell V. Luepker, MD, MS, FACC, FAHA, Co-Chairs
Kurt J. Greenlund, PHD, Kathryn A. Taubert, PHD, FAHA, Michael J. Roy, MD, MPH, FACP,
Rose Marie Robertson, MD, FACC, FAHA
Introduction
The role of infectious agents in cardiovascular disease has been
well-recognized since the early 20th century (1), when in a few
decades, introduction of antibiotics and public health efforts
made it possible to control many infectious diseases. Subse-
quently, considerable attention was paid to the role of multiple
noninfectious risk factors in the atherosclerotic process. More
recently, investigators have addressed the possibility that infec-
tions may complicate existing cardiovascular diseases and
advance the atherosclerotic process. It is also possible that exposure
to infectious agents and toxins may have more direct cardiovas-
cular effects and play an important role in inflammation (2). The
significant role of inflammation in many cardiovascular diseases
(2) and the identification of new emerging infections (e.g., HIV,
Ebola, SARS, and avian influenza) have renewed interest in the
potential role of infections in cardiovascular diseases. Current
knowledge of these relationships is largely based on anecdotal
reports; no prospective studies or well-developed research pro-
grams on this issue are currently available.
Task Force IV discussed issues surrounding basic, clinical,
and population science research and training needs with
regards to emerging infectious diseases and biological threats.
Although some data are available on the manifestations of and
therapies for some infectious agents (e.g., influenza) (3) and
some preventive interventions have been developed (e.g.,
smallpox vaccination) (4), little information is available on the
cardiovascular effects of most emerging infectious diseases and
potential bioterrorism agents. Comprehensive, targeted re-
search is needed to assess the nature and extent of the effects of
emerging and re-emerging infections, as well as other biologic
threats, such as Category A, B, and C agents,1 on the
cardiovascular system. This research should address clinical
manifestations, diagnostic methods, and the efficacy of various
preventive and therapeutic interventions. Translational and
interdisciplinary research approaches are also needed to analyze
data from basic, animal, clinical, and population-based studies
to reach a comprehensive understanding of this topic.
The group recognized that lessons can be learned from
the effects of both natural and unnatural disasters for
assessing the secondary effects of emerging diseases and
biological agents on the cardiovascular system (5–7). In
general, epidemiologic, clinical, and basic research can help
clarify the pathogenesis, identify people at highest risk for
potential cardiovascular complications, identify the most
effective diagnostic and therapeutic approaches, and estab-
lish effective prevention and rehabilitation methods.
In this report, we provide an overview of the limited
epidemiologic research that has been conducted connecting
cardiovascular and infectious diseases and identify gaps in
the literature. We describe the need for surveillance systems
that might increase our ability to quickly identify disease
outbreaks and track their course and cardiovascular impact.
We also address the clinical studies required to improve our
ability to diagnose, prevent, and treat the potential cardio-
vascular complications of bioterrorist agents and diseases, as
well as the basic research that could be useful for clarifying
the mechanisms of infectious disease. We describe the
training needs required for both health care professionals
and high-risk members of the public to help them recognize
and respond appropriately to bioterrorist threats that could
have cardiovascular effects. The report ends with our sug-
gestions for basic, clinical, and epidemiological research and
for training for professional and lay populations.
Epidemiologic Studies
Traditionally, epidemiologic or population studies have
played a key role in gaining insight into the different aspects
of infectious diseases, including emerging or re-emerging
infections and their complications. The epidemiologic lit-
erature focuses primarily on the immediate morbidity and
1Based on the categorization scheme of the Centers for Disease Control and
Prevention (CDC). Agents in Category A are the highest priority because they can be
easily disseminated or transmitted from person to person; result in high mortality rates
and have the potential for major public health impact; might cause public panic and
social disruption; and require special action for public health preparedness. Agents in
Categories B and C have lower priority. For more information on this categorization
scheme and a list of agents in each category, see the CDC’s list of bioterrorism agents
and diseases at: http://www.bt.cdc.gov/agent/agentlist-category.asp.
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mortality or the long-term noncardiovascular complications
of these infectious diseases.
New epidemiologic studies are needed to identify, char-
acterize, and prioritize different classes of emerging infec-
tions as well as biological toxins with a potential for causing
cardiovascular complications and quantify their cardiovas-
cular burden. These effects may be direct or indirect, or even
occur as iatrogenic complications of preventive or therapeu-
tic efforts. These infections may occur sporadically or in
epidemics or pandemics (8–12). They may occur naturally
(e.g., epidemic and pandemic influenza, West Nile virus),
accidentally (e.g., accidental release of smallpox virus), or
through acts of bioterrorism (e.g., smallpox, anthrax in the
U.S. in 2001, and ricin) (9,13–16). Also worthy of consid-
eration are potential side effects of mass public health
interventions, such as smallpox or anthrax vaccination, in
response to potential threats (4,17,18).
Infectious disease outbreaks have been associated with
excess cardiovascular mortality (19–21). Epidemiological
studies are needed to identify both the acute (e.g., assess-
ment of influenza epidemics) and potential chronic effects
(e.g., increased risk of atherosclerotic events) of such out-
breaks (22). Studies of available data on cardiac patients
after major disasters such as earthquakes or the September
11, 2001, attacks could be helpful in predicting the long-
term psychological and other effects of other events such as
infectious disease outbreaks or biological threats on individ-
uals with existing cardiovascular disease (23–25).
Available databases and retrospective studies should be
used to assess whether historical outbreaks of infectious
diseases and interventions to control them (e.g., flu epidem-
ics, SARS, smallpox vaccination programs) were consis-
tently associated with an increase in cardiovascular compli-
cations (19–21,24,26–29). When possible, such studies
might examine issues such as identifying the excess risk of
cardiovascular complications associated with each threat,
time–response relationships, whether the disease is associ-
ated with both long-term chronic cardiovascular effects and
acute effects, and whether certain populations have an
increased risk following such events. Potential data sources
include death certificates, clinical examinations of survivors,
medical records, emergency room admission records, and
billing records. Predefined criteria should be established to
identify whether the number of cardiovascular events actu-
ally increases following an outbreak, assess possible cause–
effect relationships, and evaluate the impact in vulnerable
populations, such as persons with pre-existing cardiovascu-
lar disease or atherosclerosis.
Emerging infections may have primary or secondary
effects on the cardiovascular system. The primary impact of
a disaster should be evaluated in the immediate vicinity of
the threat. Indirect and secondary impacts (such as psycho-
logical effects) may be evaluated in locations that were not
direct targets of the event. These psychological evaluations
should be incorporated into an evaluation program designed
to assess cardiovascular implications, because they could
have a significant impact on the pathogenesis of cardiovas-
cular disease and have implications for therapy (30–32).
Research Infrastructure
for Surveillance and Response
When indicated, a cardiovascular component needs to be
designed and implemented into surveillance systems at
regional, national, and global levels to increase our ability
for early detection of cardiovascular effects of diseases of
interest (33). Surveillance should also include monitoring of
disease outbreaks in animals for diseases affecting nonhu-
man hosts (34).
Syndromic surveillance is comprised of systems designed
to detect in a timely manner signals of increasing events
based on monitoring patterns of hospitalizations, emergency
room visits, emergency medical services data, billing
records, prescriptions, and so on (35–38). Adhering to
standard national protocols for data definition and collec-
tion, as well as ensuring compatibility of electronic medical
record systems, are critical factors for developing syndromic
surveillance systems. State and federal law should permit
syndromic surveillance to ensure morbidity and mortality
follow-up because syndromic surveillance may often include
cardiovascular data and can potentially detect disease out-
breaks sooner and with a higher sensitivity than traditional
surveillance systems, which depend on active reporting of
diagnosed cases (38–41). The growing use of electronic
medical records could facilitate timely surveillance and easy
inclusion of cardiovascular data.
In the meeting the group discussed that although issues
of privacy and confidentiality are important, the Privacy
Rule of the Health Insurance Portability and Accountability
Act of 1996 allows necessary disclosures of protected per-
sonal health information to public health authorities for the
purpose of preventing or controlling disease, injury, or
disability.
Clinical Studies
Very little information is available about the likely impact of
most emerging infections and potential bioterrorism agents
on the cardiovascular system. Most prior studies have
concentrated on noncardiac effects and few experimental
studies have been done. Clinical studies, therefore, are
needed to assess the pathophysiology of each threat’s impact
on the cardiovascular system and its components (28).
Potential cardiovascular effects of emerging infectious
diseases and biological threats include damage to the myo-
cardium, endocardium, pericardium, and blood vessels;
destabilization of vulnerable plaques; accelerated progres-
sion of atherosclerosis; modification of risk factors; valvular
damage; conduction system abnormalities; prothrombotic
effects; and psychological sequelae. Bioterrorism agents may
serve as a primary cause of cardiac disease in people without
pre-existing cardiovascular disease and may have secondary
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cardiovascular effects in populations with atherosclerosis or
other chronic cardiovascular diseases.
It may be possible to conduct clinical trials/observational
studies in healthy volunteers for low-risk interventions (e.g.,
smallpox vaccination in military service members) (17,28).
Clinical observations and case series in the setting of
disasters may be feasible, but these will be unplanned and
unpredicted (26,27). When experimental studies are im-
practical or not possible for ethical reasons, disease effects
may be monitored in subjects with known exposures or who
are at high risk for exposure and in health care professionals
caring for exposed people. Cardiovascular effects should be
carefully recorded and subjects’ responses to different inter-
ventions should be monitored. Careful monitoring of these
groups may help develop diagnostic methods for rapid
identification of an emerging infectious disease or terrorist
threat and facilitate the identification of effective preventive
or therapeutic interventions.
Examples of potential natural experiments include studies
of military personnel after experimental vaccinations and
treatments and of individuals who have survived disasters, as
well as long-term follow-up of people who have survived
infections (e.g., influenza, anthrax) (28). To study the
cardiovascular effects of mass smallpox vaccination efforts,
for example, investigators could monitor electrocardiogra-
phy, echocardiography, and troponin measurements in a
subset of asymptomatic subjects following smallpox vacci-
nation. Different risk groups could be followed to determine
whether the number of cardiac events increases after the
vaccine is administered. Different therapeutic measures
could also be assessed in these individuals, and the results
could be compared to yield the best strategy. Since plaque
disruption has been proposed as an etiology for cardiac
effects, analyzing the mechanisms of known plaque disrup-
tion triggers could yield a pathogenesis model of infectious
etiologies (24,25,32,42).
In addition to specific therapies for each infectious agent
(e.g., antibiotics against specific infectious agents, antidotes
for toxins), nonspecific cardioprotective medications may be
tested in these natural settings. Recent reports suggest
potential benefit from the use of beta blockers for immediate
survivors following major stressful events to reduce the risk
of posttraumatic stress disorder (43). Beta blockers may also
be effective and merit further research in preventing acute
coronary syndromes, especially in high-risk patients, follow-
ing terrorist events or disasters. Other potentially effective
therapies for various cardiac complications include aspirin,
antiplatelet drugs, anti-inflammatory drugs, and intravenous
immunoglobulins. The efficacy and cost–benefit ratio of
such interventions when many patients are already receiving
these drugs are largely unknown.
Outbreaks of emerging infections are unpredictable, and
it is difficult or even impossible to make substantial changes
in the clinical care of high-risk individuals within a short
time period. Therefore, considerable effort should be fo-
cused on increasing the adoption rate of proven preventive
therapies in people with cardiovascular disease to decrease
their likelihood of cardiovascular complications in a crisis.
For example, the best way to improve vaccine coverage rates
during influenza pandemics is to improve interpandemic
vaccine coverage rates (44).
Vaccination
Although the influenza vaccine has been shown to reduce
the risk of cardiovascular events (3), a small number of
cardiovascular events have been reported following smallpox
vaccination, including myopericarditis and rare ischemic
events associated with pre-existing atherosclerotic disease or
risk factors, although the relationship of acute myocardial
infarction to smallpox vaccination is uncertain. The cardio-
vascular effects of vaccines for other infectious agents are not
readily recognized; however, as new vaccines are developed
and used, their cardiovascular effects should be closely
monitored. With any vaccination, a general stimulation of
the immune system could cause a flare-up of the inflamma-
tory process in the atherosclerotic plaques, endocardium,
myocardium, or pericardium, exacerbating inflammatory
disease. Also, the widespread activation of inflammatory
cells could be associated with activation of macrophages in
vulnerable plaques, triggering heart attacks. Therefore, an
increased early hazard is a possibility after any vaccination
program and needs to be monitored and ruled out if
possible. However, B-cell activation (part of the humoral
response) may be protective against atherosclerosis (45).
Research is needed on the potential cardiovascular benefits
and complications of immunization and on public attitudes
regarding the benefits and risks of vaccination in general.
Clinical Guidelines
Recommendations on the diagnosis, prevention, and
treatment of cardiovascular complications of biological
threats are critically needed. When applicable, consensus
guidelines for different infectious agents that could be
used for bioterrorism (14,46 –50) should address cardio-
vascular effects and the related diagnostic, preventive, and
therapeutic approaches.
Basic Studies
In the absence of controlled clinical experiments and given
the high-risk nature of many threats that make clinical
studies either difficult or impossible, basic laboratory and
animal studies may provide valuable information on the
cardiovascular mechanisms of infectious disease and help
prepare for bioterrorism threats.
The availability of several good animal models of athero-
sclerosis should enable scientists to determine the effect of
many infections and biological toxins (e.g., ricin) on ath-
erosclerotic plaques, the coagulation system, circulatory and
hemodynamic components, and the conducting system
(51–54). Infections may trigger acute destabilization of
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vulnerable plaques, leading to acute coronary syndromes (in
short-term) or they can accelerate the atherosclerosis pro-
cess and increase patients’ risk over years (3,51,55,56). The
efficacy of different classes of medications in preventing
complications could also be assessed in these animal models.
Training
Professional Training
Training strategies should target professional leadership,
workforces, and organizations. Issues of the cardiovascu-
lar effects of emerging infections need to be added to and
incorporated into existing training programs. These ed-
ucational programs may also be incorporated into con-
tinuing medical education programs for health care
providers.
When applicable, a cardiovascular component may be
incorporated into current infectious disease and biologic
agent outbreak training programs. Consensus-based recom-
mendations for responding to different bioterrorist threats
describing the measures to be taken by medical and public
health professionals can be used as educational materials for
this purpose (14,47–50,57).
Public Education
As the first and third leading causes of death in the U.S.,
Task Force IV members noted that cardiac and cerebrovas-
cular events will continue during infectious disease out-
breaks and bioterrorist events. Individuals who have or are
at risk for cardiovascular disease should adhere to the
well-documented evidence-based guidelines for primary and
secondary prevention of cardiovascular diseases (such as
those developed by the American College of Cardiology and
American Heart Association) (58–60). The best way to
ensure that patients will follow these guidelines at the time
of a crisis is to improve general adherence to these guide-
lines. The public can provide additional protection for those
at risk of cardiovascular complications by learning cardio-
pulmonary resuscitation techniques and how to use auto-
mated external defibrillators (61). Educational materials
should be developed for the public regarding the potential
impact of emerging infectious diseases and biological threats
on cardiovascular disease.
Future Considerations
Based on this discussion of the research and training needs
related to the cardiovascular effects of potential bioterrorist
agents, Task Force IV suggested that addressing the follow-
ing issues may help to improve response and cardiovascular
outcomes of potential emerging infectious diseases and
biological threats:
1. Multidisciplinary translational research should assess
the full spectrum of the effects of potential bioterrorism
agents on the cardiovascular system.
2. To determine the incidence and significance of cardio-
vascular complications of smallpox or other vaccinations,
epidemiologic studies should be conducted in conjunc-
tion with vaccination programs, and animal studies
should be conducted to further delineate the extent and
nature of potential cardiovascular complications.
3. Public health surveillance should be established to mon-
itor incidence and trends of cardiovascular diseases. The
proposed surveillance system should be capable of detect-
ing increased rates of cardiac events (e.g., acute coronary
syndromes, myocarditis) with high sensitivity and in a
timely manner. Following relevant events (e.g., massive
vaccination programs or disease outbreaks) with a high
risk for cardiovascular adverse effects, reporting of cardiac
complications should be encouraged and even required.
The feasibility of reporting cardiac events following rel-
evant events should be explored. Privacy and legal issues
need to be addressed.
4. When applicable, a cardiovascular disease response com-
ponent must be incorporated into response plans for
emerging infections and bioterrorism events with poten-
tial adverse cardiac effects. Health care providers and first
responders should be trained about the common and
important cardiac effects of emerging infections. Related
scenarios should be tested in drills and tabletop exercises.
When necessary, educational material on potential car-
diac effects of biological agents should be developed for
the public and made widely available.
5. An influenza pandemic is considered likely to occur and,
therefore, must be considered a high-priority research
issue. The lessons learned in trying to prepare for such a
pandemic might be applied to preparations for outbreaks
of other emerging infections and bioterrorist threats.
6. The legal and ethical issues regarding equitable distri-
bution of scarce resources to cardiac patients at times
of crisis require attention, and solutions for different
scenarios should be outlined.
7. Environmental safety procedures for catheterization
laboratories and coronary or intensive care units that
care for patients infected with highly contagious agents
must be defined and implemented.
8. In the absence of clinical trials, the role of vaccination,
antitoxins and anti-infective therapy, and nonspecific
cardioprotective therapies in bioterrorism threats
should be analyzed and published by consensus panels.
9. Research is needed on public attitudes regarding the
benefits, risks, and acceptance of vaccination from a
cardiovascular point of view.
10. Animal models should be used to evaluate the cardio-
vascular effects of potential threats related to emerging
infections (e.g., avian influenza or smallpox vaccine)
as well as the efficacy of preventive and therapeutic
measures.
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Conclusions
Natural outbreak of emerging infections or release of bio-
logic agents during a bioterrorism attack could have a
considerable impact on the cardiovascular systems of those
exposed to the agents, but little information is available on
related mechanisms, clinical presentations, or appropriate
diagnostic, preventive, and therapeutic measures. Therefore,
research on these issues is needed at the population, clinical,
and basic science levels. In addition, health care providers
need training on how to identify and care for those who
experience cardiovascular effects from a bioterrorist attack.
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